Thomas E. Stinchcombe, MD
Department of Hematology/Oncology
University of North Carolina
Chapel Hill, NC
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
Lung cancer is the leading cause of worldwide cancer mortality and is responsible for more deaths annually in the United States than the combination of breast, colorectal, and prostate cancer. About 87% of lung cancer cases in the U.S. are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage with poor overall survival for most patients. Advanced NSCLC is incurable, and thus the goal of therapy is to give patients the best quality of life for the longest period of time.
Recently, treatment for advanced NSCLC has expanded beyond chemotherapy as the cornerstone of treatment to include a new generation of targeted therapies that interfere with the cellular pathways involved in tumor growth, progression, and cell death. The use of molecularly targeted therapies represents a significant advance in the treatment of NSCLC. To improve outcomes for patients with NSCLC, oncologists are encouraged to focus increasingly more attention on the underlying molecular abnormalities in advanced NSCLC. Molecular markers provide additional insight to help clinicians identify patients most likely to benefit from specific targeted therapies.
. Target Audience
This educational activity is designed to meet the needs of oncologists and those who manage patients with cancer.
Upon completion of this educational activity, the participant should be able to:
Describe the use of predictive biomarkers in advanced NSCLC
Discuss how biomarkers may change the management of patients with advanced NSCLC
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.
Dr. Stinchcombe discloses that he is an advisory board member at Genentech.
Office of CME:
Zalman S. Agus, MD has no relevant financial relationships to disclose.
Mila Kostic has no relevant financial relationships to disclose.
Medical Communications Media, Inc.:
Sara Thier, PhD, MPH has no relevant financial relationships to disclose.
Elizabeth Paczolt, MD has no relevant financial relationships to disclose.
Investigational and/or Off-Label Use of Commercial Products and Devices:
The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. In this educational activity, the faculty discusses the use of erlotinib as a first-line therapy. Currently, the FDA has only approved erlotinib as a second- or third-line therapy.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and Medical Communications Media, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: September 19, 2011
Last review date: September 19, 2011
Expiration date: September 19, 2012 Commercial Support Statements
Supported by educational grants from Astellas Pharma Global Development, Inc. and Pfizer Inc.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 100%
* You are allowed one retake
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
* Windows: Latest release of Safari, Internet Explorer 6/7 or Mozilla/Firefox.
* Macintosh: Latest release of Safari or Mozilla/Firefox.
There is no charge for CME credit.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher,the Perelman School of Medicine at the University of Pennsylvania, Astellas Pharma Global Development, Inc., or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.